Premium
Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma
Author(s) -
Ketterl Tyler G.,
Messinger Yoav H.,
Niess Dawn R.,
Gilles Elizabeth,
Engel William Keith,
Perkins Joanna L.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24646
Subject(s) - medicine , ofatumumab , rituximab , refractory (planetary science) , methotrexate , neuroblastoma , blood cancer , monoclonal antibody , monoclonal , oncology , gastroenterology , immunology , antibody , cancer , lymphoma , physics , astrobiology , biology , genetics , cell culture
Opsoclonus‐myoclonus syndrome (OMS) may be associated with ANNA‐1 (anti‐Hu) autoantibodies. The standard treatment with IVIG, steroids, and anti‐CD20 monoclonal antibody may fail, and optimal therapy is unknown. A patient developed OMS with high‐titer ANNA‐1 following recovery from neuroblastoma. She failed standard therapy and had only transient response to rituximab. Treatment with the humanized anti‐CD20 monoclonal antibody ofatumumab combined with methotrexate resulted in transient neurologic improvement and decrease of ANNA‐1. This suggests that ofatumumab combined with methotrexate should further be considered OMS patients, particularly in refractory disease. Pediatr Blood Cancer 2013;60:E163–E165. © 2013 Wiley Periodicals, Inc.